Beauty School is In Session -- Create a No-Makeup, Makeup Look
Allergan, the makers of ACZONE®(dapsone) Gel 5% team up with celebrity makeup artist Julianne Kaye on new video tutorial
IRVINE, Calif., Aug. 20, 2014 /PRNewswire/ -- Renowned beauty expert and makeup artist to the stars Julianne Kaye is partnering with Allergan, the makers of ACZONE® (dapsone) Gel 5%, the No. 1 prescribed retinoid-free acne brand in the U.S., to offer expert skincare and makeup tips in an exclusive video posted today on http://www.aczone.com/beauty-tips.1 ACZONE® Gel is a prescription medicine used on your skin (topical) to treat acne in people 12 years and older.
"This time of year, my clients— particularly those with acne—are often concerned about being poolside or at the beach because it's not the best environment for heavy makeup," said Kaye. "The good news is you can still look fresh and pretty without loading on the concealer and foundation. That's why I am excited to partner with Allergan, the makers of ACZONE® Gel, to share tips and tricks for achieving one of my favorite looks. Makeup, of course, can only get you so far, so it's important to see a dermatologist to address any chronic skin conditions like acne."2
Acne is the most common skin condition in the United States, affecting 50 million Americans.3 Nearly 85% of people have acne at some point in their lives.3 In many cases, adults—particularly women—in their 20s, 30s, 40s, and even 50s can continue to have acne.3 However, people living with this chronic condition don't have to simply cope with their condition.2 Rather than self-treating or managing it alone, acne-sufferers can work with their dermatologist to identify treatments that are right for their skin and routine.
"The summer heat is not kind to acne-prone skin or the layers of makeup that we use to cover the blemishes and imperfections," said Doris Day, MD, MA, Clinical Associate Professor of Dermatology at New York University Langone Medical Center. "One medication I prescribe for acne lesions that can be worn under makeup is ACZONE® Gel. ACZONE® Gel does not make acne worse before it gets better. ACZONE® Gel is not known to cause sun sensitivity.4 And remember, sunscreen is a must-have regardless of your skin type."
To watch the video and for more skincare tips, please visit http://www.aczone.com/beauty-tips.
ACZONE® Gel is a prescription medicine used on your skin (topical) to treat acne in people 12 years and older.
IMPORTANT SAFETY INFORMATION
Do not use ACZONE® Gel if you are allergic to any of the ingredients in ACZONE® Gel or if you are younger than 12 years of age.
Tell your doctor about all of your medical conditions, including if you have glucose-6-phosphate dehydrogenase deficiency (G6PD) which may put you at a greater risk for developing a low red blood cell count. If you experience signs and symptoms such as back pain, breathlessness, tiredness/weakness with daily activities, dark-brown urine, high fever, and yellow or pale skin, stop use and call your doctor immediately.
The most common side effects of ACZONE® Gel are dryness, redness, oiliness, and peeling of the skin being treated.
Talk to your doctor about any medications you're using including topical benzoyl peroxide (BPO). Use of BPO with ACZONE® Gel may cause your skin to temporarily turn yellow or orange at the site of application.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for full Prescribing Information or visit www.aczone.com
Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 11,700 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com.
This press release contains "forward‐looking statements," including but not limited to, the statements by Ms. Kaye and Dr. Day as well as other statements regarding the safety and efficacy of ACZONE®. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and pharmaceutical market conditions; challenges related to achieving regulatory approval from the FDA on a timely and cost‐efficient manner; technological advances and patents attained by competitors; inconsistency of treatment results among patients; potential difficulties in manufacturing; challenges related to new product marketing, such as the unpredictability or market acceptance for new products and/or the acceptance of new indications for such products; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward‐looking statements except as required by law. Additional information concerning these and other risks can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's most recent Annual Report on Form 10‐K and any subsequent Quarterly Reports on Form 10‐Q. Copies of Allergan's press releases and additional information about Allergan are available at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 1‐714‐246‐4636.
Heather Katt (714)697-2981; (714)246-6224 (media)
Jessica Chao (714)586-7707; (714)246-3151 (media)
© 2014 Allergan, Inc.
® marks owned by Allergan, Inc.
1 IMS Health, Inc. Monthly IMS National Prescription Audit Data. April 2008 – March 2014
2 Gollnick H et al. Can We Define Acne as a Chronic Disease? Am J Clin Dermatol. 2008:9(5): 279-284.
3 American Academy of Dermatology. "Stats and Facts: Acne." Available online at http://www.aad.org/mediaresources/stats-and-facts/conditions/acne. Last accessed on October 17, 2013.
4 DraelosZD, Carter E, Maloney JM, et al; For United States/Canada DapsoneGel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsonegel, 5% for the treatment of acne vulgaris. J Am AcadDermatol. 2007;56(3):439.e1-439.e10.